Conference item icon

Conference item

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study

Subtitle:
conference abstract
Publication status:
Published
Peer review status:
Reviewed (other)

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDORMS
Subgroup:
Botnar Research Centre
Role:
Author
ORCID:
0000-0002-4756-663X
Expand authors...
Publisher:
BMJ Publishing Group Limited Publisher's website
Volume:
77
Pages:
1010-1011
Publication date:
2018-06-12
DOI:
EISSN:
1468-2060
ISSN:
0003-4967
Pubs id:
pubs:930945
URN:
uri:34a929e9-eee5-4bfc-ab8d-f37def274b76
UUID:
uuid:34a929e9-eee5-4bfc-ab8d-f37def274b76
Local pid:
pubs:930945
Keywords:

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP